Моксифлоксацин: настоящее и будущее в ступенчатой терапии

Клиническая Микробиология и Антимикробная Химиотерапия. 2003; 5(1):19-31

​ Страчунский Л.С., Веселов А.В., Кречиков В.А.
моксифлоксацин фторхинолоны пневмония ступенчатая терапия
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2003; 5(1):19-31

Аннотация

Моксифлоксацин – новый 8-метоксихинолон широкого спектра действия с высокой активностью в отношении как грам(+) и грам(–) аэробов, так и внутриклеточных возбудителей и анаэробов. Обладает активностью в отношении микроорганизмов, резистентных к другим классам антибактериальных препаратов, включая пенициллино- и макролидорезистентные пневмококки и β-лактамазопродуцирующие штаммы Haemophilus influenzae. Высокая активность против перечисленных возбудителей и хороший фармакокинетический профиль позволяют применять моксифлоксацин для терапии респираторных инфекций. Одним из подходов является ступенчатая терапия, при которой моксифлоксацин, по данным многочисленных контролируемых клинических исследований, продемонстрировал высокую клиническую эффективность и безопасность у пациентов с внебольничной пневмонией. В статье представлен обзор результатов клинических исследований ступенчатой терапии моксифлоксацином при лечении внебольничной пневмонии и сделана попытка оценить возможные перспективы его дальнейшего применения.

  • 1. Ricci V., Piddock L. Characterization of the QRDR ofgyrA of Bacteroides fragilis and role in fluoroquinoloneresistance. 38th ICAAC†; 1998 Sep 24–27; San Diego,USA. p. 121.
  • 2. Jones M., Staple A., Critchley I., et al. Benchmarking thein vitroactivities of moxifloxacin and comparator agentsagainst resent respiratory isolates from 377 medical cen-ters throughout the United States. Antimicrob AgentsChemother 2000;44:2645-52.
  • 3. Johnson A., Livermore D., Warner M., James D., GeorgeR. Activity of moxifloxacin against invasive and multire-sistant pneumococci from England and Wales. 39thICAAC†;1999 Sep 26–29; San Francisco, USA. p. 255.
  • 4. Milatovic D., Schmitz F., Brisse S., Verhoef J., Fluit A.In vitroactivities of sitafloxacin (DU-6859a) and sixother fluoroquinolones against 8796 clinical bacterial iso-lates. Antimicrob Agents Chemother 2000;44:1102-7.
  • 5. Buxbaum A., Straschil U., Moser C., Graninger W.,Georgopoulos A. Comparative susceptibility to penicillinand quinolones of 1385Streptococcus pneumoniaeiso-lates. J Antimicrob Chemother 1999;43 (Suppl B):13-8.
  • 6. Souli M., Weneersten C., Eliopoulos G.In vitroactivityof BAY 12-8039, a novel 8-methoxyquinolone, againstspecies representative of respiratory tract infections.37th ICAAC†, 1997: Sep 28 – Oct 1; Toronto, Canada.Poster F126.
  • 7. Blondeau J., Church D., Laskowski R., Borsos S. Compa-rative activity of moxifloxacin and other quinolonesagainst macrolide sensitive and resistantStreptococcuspyogenes. J Antimicrob Chemother 1999;44(Suppl A):131.
  • 8. Jones M., Visser M., Klootwijk M., Heisig P., Verhoef J.,Schmitz F. Comparative activities of clinafloxacin,grepafloxacin, levofloxacin, moxifloxacin, ofloxacin,sparfloxacin, and trovafloxacin and nonquinolones line-zolid, quinupristin–dalfopristin, gentamicin, and van-comycin against clinical isolates of ciprofloxacin-resis-tant and -susceptibleStaphylococcus aureusstrains.Antimicrob Agents Chemother 1999;43:421-3.
  • 9. Kretchikov V.A., Dekhnich A.V., Startchounski L.S.Comparative activity of old and new quinolones againstnosocomialStaphylococcus aureus. 12th ECCMID♦;2002 Apr 24–27; Milan, Italy. p. 261.
  • 10. Fass R.In vitroactivity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother1997;41:1818-24.
  • 11. Woodcock J., Andrews J., Boswell F., Brenwald N., Wi-se R.In vitroactivity of BAY 12-8039, a new fluoro-quinolone. Antimicrob Agents Chemother 1997;41:101-6.
  • 12. Кречиков В., Эйдельштейн И. Активность левофлок-сацина и моксифлоксацина в отношении ципрофлок-сацин-нечувствительных нозокомиальных штаммов,продуцентовβ-лактамаз расширенного спектра(ESBL). Клиническая Микробиология и Антимикробная Химиотерапия 2001;3 Прил 1: 23.
  • 13. Duffy L., Kempf M., Crabb D., Wall W., Herrington J.Invitroactivity of moxifloxacin and six other new antimi-crobials againstMycoplasma pneumoniae. 39th ICAAC†;1999 Sep 26–29; San Francisco, USA. p. 252.
  • 14. Bebear C.M., Renaudin H., Boudjadja A., Bebear C.Invitroactivity of BAY 12-8039, a new fluoroquinoloneagainst mycoplasmas. Antimicrob Agents Chemother1998;42:703-4.
  • 15. Ullmann U., Schubert S., Krausse R. Comparativein vitroactivity of levofloxacin, other fluoroquinolones, doxycyc-line and erythromycin againstUreaplasma urealyticumandMycoplasma hominis. J Antimicrob Chemother1999;43 (Suppl C):33-6.
  • 16. Schulin T., Wennersten C., Ferraro M., Moellering R. Jr.,Eliopoulos G. Susceptibilities ofLegionellaspp. to newerantimicrobialsin vitro. Antimicrob Agents Chemother1998;42:1520-3.
  • 17. Gomez-Lus R., Adrian F., del Campo R., et al.Comparativein vitrobacteriostatic and bactericidalactivity of trovafloxacin, levofloxacin and moxifloxacinagainst clinical and environmental isolates ofLegionellaspp. Int J Antimicrob Agents 2001;18:49-54.
  • 18. Alcala L., Ruiz-Serrano M., Garcia-Arias V., Jimenez S.,Garcia de Viedma D., Bouza E.In vitroactivity of moxi-floxacin, ciprofloxacin, levofloxacin and ofloxacin againstMycobacterium tuberculosisstrains including those multi-ply-resistant to first line antituberculous drugs. 42ndICAAC; 2002 Sep 27–30; San Diego, USA. p. 155.
  • 19. Rivera-Martínez E., Pérez-González E., Garcia M.,Orrantia-Gradín R, Hernández-Oliva G, Torres-Gutierrez Rubro A. Determination of thein vitrosuscep-tibility of different strains ofM. tuberculosisto BAY12-8039 and other antituberculosis agents. 8th ICID‡;1998 May 15–18; Boston, USA. p. 173-4.
  • 20. Nord C., Edlund C. Susceptibility of anaerobic bacteriato BAY 12-8039, a new methoxyquinolone. Clin MicrobInfection 1997;3 (Suppl 2):285.
  • 21. MacGowan A., Bowker K., Holt H., Wootton M., Ree-ves D. BAY 12-8039, a new 8-methoxyquinolone: com-parativein vitroactivity with nine other antimicrobialsagainst anaerobic bacteria. J Antimicrob Chemother1997;40:503-9.
  • 22. Stass H., Kubitza D. Pharmacokinetics and elimination ofmoxifloxacin after oral and intravenous administration inman. J Antimicrob Chemother 1999;43 (Suppl B):83-90.
  • 23. Ballow C., Lettieri J., Agarwal V., Liu P., Stass H., Sul-livan J. Absolute bioavailability of moxifloxacin. ClinTher 1999;21:513-22.
  • 24. Wise R., Andrews J., Marshall G., Hartman G. Phar-macokinetics and inflammatory-fluid penetration ofmoxifloxacin following oral or intravenous administra-tion. Antimicrob Agents Chemother 1999;43:1508-10.
  • 25. Lubasch A., Keller I., Borner K., Koeppe P., Lode H. Com-parative pharmacokinetics of ciprofloxacin, gatifloxacin,grepafloxacin, levofloxacin, trovafloxacin and moxi-floxacin after single oral administration in healthy volun-teers. Antimicrob Agents Chemother 2000;44: 2600-3.
  • 26. Lettieri J., Vargas R., Agarwal V., Liu P. Effect of food onthe pharmacokinetics of a single oral dose of moxifloxacin400 mg in healthy male volunteers. Clin Pharmacokinet2001;40 (Suppl 1):19-25.
  • 27. Stass H., Kubitza D. Effects of dairy products on the oralbioavailability of moxifloxacin, a novel 8-methoxyfluoro-quinolone, in healthy volunteers. Clin Pharmacokinet2001;40 (Suppl 1):33-8.
  • 28. Sullivan J., Lettieri J., Liu P., Heller A. The influence ofage and gender on the pharmacokinetics of moxifloxacin.Clin Pharmacokinet 2001;40 (Suppl 1):11-8.
  • 29. Stass H., Halabi A., Delesen H. No dose adjustment need-ed for patients with renal impairment receiving oral BAY12-8039 (M). 38th ICAAC†; 1998 Sep 24–27; SanDiego, USA. p. 5.
  • 30. Stass H., Kubitza D. No dose adjustment is needed formoxifloxacin (MOX) in subjects suffering from hepaticimpairment (HI). Clin Microb Infection 1999;5(Suppl 3):291.
  • 31. Zhanel G., Walters M., Karlowsky J., Laing N., Hoban D.Activity of free (unbound) fluoroquinolone serum con-centrations versus multi-drug resistantStreptococcuspneumoniaeusing anin vitropharmacodynamic model.40th ICAAC†; 2000 Sep 17–20; Toronto, Canada. p. 7.
  • 32. Wright D., Brown G., Peterson M., Rotschafer J. Appli-cation of fluoroquinolones pharmacodynamics. JAntimicrob Chemother 2000;46:669-83.
  • 33. Jewesson P. Cost-effectiveness and value of an IV switch.PharmacoEconomics 1994;5 (Suppl 2):20-6.
  • 34. Jewesson P. Pharmaceutical, pharmacokinetic and otherconsidera-tions for intravenous to oral stepdown therapy.Can Infect Dis J 1995;6 (Suppl A):11-6.
  • 35. Ramirez J.A. Managing antiinfective therapy of commu-nity-acquired pneumonia in the hospital setting: focus onswitch therapy. Pharmacotherapy 2001;21:79S-82S.
  • 36. Quintiliani R., Nightingale C., Crowe H. et al. Strategicantibiotic decision-making at the formulary level. Rev InfDis 1991;13:S770-7.
  • 37. Ramirez J. Advances in antibiotic use: switch therapy.Curr Ther Res 1993;55 (A):30-4.
  • 38. Janknegt R., van der Meer J. Sequential therapy withintravenous and oral cephalosporins. J AntimicrobChemother 1994;33: 169-77.
  • 39. Страчунский Л.С., Розенсон О.Л. Ступенчатая тера-пия: новый подход к применению антибактериальныхпрепаратов. Клин фармакол тер 1997;6:20-4.
  • 40. Eisen S., Miller D., Woodward R., et al. The effect of pre-scribed daily dose frequency on patient medication com-pliance. Arch Intern Med 1990;150:1881-4.
  • 41. Nathwani D. Cost-effectiveness considerations for combination therapies. In: Antibiotic combination therapy –the role of ciprofloxacin. Cambridge Medical Publica-tions, 1997;19.
  • 42. Quintiliani R., Cooper В., Briceland L., et al. Economicimpact of streamlining antibiotic administration. Am JMed 1987;82 (Suppl 4A):391-4.
  • 43. Jewesson P. Economic impact of intravenous-to-oralantibacterial stepdown therapy. Clin Drug Invest1996;11 (Suppl 2):1-9.
  • 44. Finch R., Collins O., Kubin R. IV/PO Moxifloxacin(MXF) compared with IV/PO amoxicillin/clavulanate(AMC) +/– clarithromycin (CMP) in the treatment ofcommunity acquired pneumonia (CAP) admitted to hos-pital. 11th ECCMID♦, Istanbul, Turkey, 1–4 April,2001. p. 167.
  • 45. Choudhri S.H., Hollister A.S., Haverstock D., Wein-stein D.M., Jackson P., Church D. Safety and efficacy ofsequential (IV to PO) moxifloxacin for the treatment ofcommunity-acquired pneumonia in hospitalized patients.1st International Symposium on Resistant Gram-posi-tive Infections, San Antonio, Texas, 3–5 Dec, 2000.Poster # I-14.
  • 46. Grossman C., Choudhri S., Haverstock D., Jackson P.,Church D. Moxifloxacin intravenous-to-oral switchtherapy for severe community-acquired pneumonia.CHEST 2001, Philadelphia, Pennsylvania, 4–8 Nov,2001. Poster #187
  • 47. Larsen S., Choudhri S., Haverstock D., Jackson P.,Church D. Efficacy and safety of sequential (IV to PO)moxifloxacin for treatment of community-acquired pneu-monia due to atypical pathogens. 41st ICAAC†, Chicago,Illinois, 16–19 Dec, 2001. p. 451.
  • 48. Fogarty C., Grossman C., Williams J., Haverstock D.,Church D. Efficacy and safety of moxifloxacin vs clar-ithromycin for community-acquired pneumonia. InfectMed 1999;16:748-63.
  • 49. Hoffken G., Meyer H., Sprenger K., Verhoef L. Efficacyand safety of moxifloxacin (MXF) vs clarithromycin(Klaritro) for the treatment of community-acquiredpneumonia (CAP). J Antimicrob Chemother 1999;44(Suppl A):127.
  • 50. Chodosh S., DeAvate C., Haverstock D., Aneiro L.,Church D. Short-course moxifloxacin therapy for treat-ment of acute bacterial exacerbations of chronic bronchi-tis. Resp Med 2000;94:18-27.
  • 51. Wilson R., Kubin R., Ballin I., et al. Five day moxiflo-xacin therapy compared with 7 day clarithromycin thera-py for the treatment of acute exacerbations of chronicbronchitis. J Antimicrob Chemother 1999;44: 501-13.
  • 52. Petipretz P., Arvis P., Marel M., et al. Oral moxifloxacinversus high-dosage amoxycillin in the treatment of mild-to-moderate, community-acquired, suspected pneumo-coccal pneumonia in adults. Chest 2001;119:185-95.
  • 53. Burke T., Villanueva C., Mariano H. Jr., et al. Compa-rison of moxifloxacin and cefuroxime axetil in the treat-ment of acute maxillary sinusitis. Clin Ther 1999;21:1664-77.
  • 54. Mandell L., Choudhri S.H., Kubin R. Safety assessmentof sequential IV/PO moxifloxacin in the treatment ofpatients with community-acquired pneumonia (CAP).11th ECCMID♦, Istanbul, Turkey, 1–4 April, 2001.p. 167-8.
  • 55. Iannini P.B., Kubin R., Reiter C. Over 10 million patientuses: An update on safety profile of oral moxifloxacin.42nd ICCAC†; 2002 Sep 27–30; San Diego, USA. p. 346.
  • 56. Parish L., Heyd A., Haverstock D., Church D. Efficacyand safety of moxifloxacin versus cephalexin in the treatment of mild to moderate acute uncomplicated skin andskin structure infections. J Antimicrob Chemother1999;44 (Suppl A):137.
  • 57. Leal del Rosal P., Martinez R., Fabian G., et al. Efficacyand safety of moxifloxacin vs cephalexin in the treatmentof mild to moderate uncomplicated skin and soft tissueinfections (uSSSI). J Antimicrob Chemother 1999;44(Suppl A):148.
  • 58. Leal del Rosal P., Fabian G., Vick-Fragoso R. Efficacyand safety of moxifloxacin vs cephalexin (with or withoutmetronidazole) in the treatment of mild to moderateuncomplicated skin and skin structures infections(uSSSI). 39th ICAAC†; 1999 Sep 26–29; San Francisco,USA. p. 716.
  • 59. Heystek M., Tellarini M., Schmitz H., Krasemann C. Effi-cacy and safety of moxifloxacin vs ciprofloxacin plusdoxycycline plus metronidazole for the treatment ofuncomplicated pelvic inflammatory disease (PID). JAntimicrob Chemother 1999;44 (Suppl A):143.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились